CA: A Cancer Journal for Clinicians, vol.67, pp.7-30, 2017. ,
Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database, European Journal of Gastroenterology & Hepatology. août, vol.29, issue.8, pp.904-912, 2017. ,
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States, Cancer Research. 1 juin, vol.74, issue.11, pp.2913-2934, 2014. ,
Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress, Journal of Clinical Oncology. 10 juin, vol.30, issue.17, pp.2036-2044, 2012. ,
Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration, Journal of Clinical Oncology, vol.22, issue.22, pp.4626-4657, 2004. ,
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine. 12 mai, vol.364, pp.1817-1842, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00598658
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine, New England Journal of Medicine, vol.369, issue.18, pp.1691-703, 2013. ,
Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review, Journal of Gastrointestinal Cancer. juin, vol.48, issue.2, pp.121-129, 2017. ,
How to treat pancreatic adenocarcinoma in elderly: How far can we, Journal of Geriatric Oncology, vol.8, issue.6, pp.407-419, 2017. ,
Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer, Cancer Medicine. déc, vol.6, issue.12, pp.2840-2849, 2017. ,
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions, World Journal of Gastroenterology, vol.23, issue.32, p.5875, 2017. ,
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol. juin, vol.15, issue.6, pp.2403-2416, 1997. ,
Gemcitabine in elderly patients with advanced pancreatic cancer, World Journal of Gastroenterology, vol.17, issue.30, p.3497, 2011. ,
, , 2018.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, issue.5, pp.373-83, 1986. ,
,
NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network. août, vol.15, issue.8, pp.1028-61, 2017. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline ,
, European Journal of Cancer. janv, vol.45, issue.2, pp.228-275, 2009.
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial, JNCI Journal of the National Cancer Institute. 31 janv, vol.107, issue.2, p.413, 2015. ,
Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): a « real-life » study, J Clin Oncol, 2015. ,
NABpaclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice, BMC Cancer, vol.16, issue.1 ,
Safety and efficacy of gemcitabine plus nab-paclitaxel therapy in elderly patients with advanced pancreatic cancer, Annals of Oncology, vol.28, 2017. ,
A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis, Ther Adv Med Oncol. févr, vol.9, issue.2, pp.75-82, 2017. ,
The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in ,
, Metastatic Pancreatic Cancer Patients, International Journal of Molecular Sciences. 29 mars, vol.18, issue.4, p.730, 2017.
Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis, Gastroenterology Research and Practice. 10 juin, vol.2018, pp.1-7, 2018. ,
Management of Cancer in the Older Age Person: An Approach to Complex Medical Decisions, The Oncologist. mars, vol.22, issue.3, pp.335-377, 2017. ,
, NCT02391662: a phase II study of nabpaclitaxel and gemcitabine, in elderly patients with previously untreated, metastatic pancreatic adenocarcinoma, Clinical Trials.gov
A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/? nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). BMC Cancer [Internet]. déc, vol.18, 2018. ,
, Un groupe contrôle de patients âgés de 65 à 75 ans a été constitué. Le profil de toxicité, la survie globale (SG) médiane, la survie sans progression (SSP), Méthodes: Etude rétrospective et multicentrique incluant de manière consécutive des patients de plus de 75 ans traités dans 4 hôpitaux français de janvier 2014 à mai 2018
Quarante-deux patients d'âge ? 75 ans (âge médian 78,5) et 85 patients âgés de 65 à 75 ,
, 1) ont été inclus. Les caractéristiques initiales ne différaient pas entre les 2 groupes hormis les patients de moins de 75 ans recevant plus fréquemment la chimiothérapie en 2ème, vol.70
, Le profil de tolérance était similaire. La SG médiane était de 9, vol.82, pp.87-97
, 85) chez les patients de moins de 75 ans. Respectivement, le taux de réponse objectif était de 27% vs. 17%, p=0,24) et la SSP médiane de 5,84 mois, les ? 75 ans et de 6,95 mois (IC95% 5, pp.5-8
,